Riskpilot← Back to searchSign inGet full accessTeimMed AB
ABActiveOrg 5591732234Svenskbyvägen 32General medical practice activities · NACE 8621Est. 20181-4 employees
Revenue 2025
SEK 1,9M
+6% vs 2024
EBITDA margin
34.7%
+148% vs 2024
Equity ratio
74.1%
Financial strength
Net profit 2025
SEK 501K
+91% vs 2024
| Revenue | SEK 1,9M | +6% |
| EBITDA | SEK 661K | +148% |
| Net profit | SEK 501K | +91% |
| Total assets | SEK 744K | -12% |
| Equity | SEK 552K | +93% |
| Employees | — | — |
Legal name
TeimMed AB
Org number
5591732234
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
27 september 2018
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att tillhandahålla vård- och omsorgstjänster för offentliga organisationer, privata företag och privatpersoner med uppdragsgivare, erbjuda rekryterings-tjänster av personal inom vård och därmed förenlig verksamhet.
Address
Svenskbyvägen 32
Email
adde1245@msn.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 242 | 2 006 | 1 517 | 1 798 | 1 903 |
| Staff expenses | — | −638 | — | −1 156 | −938 |
| EBITDA | 100 | 999 | −654 | 267 | 661 |
| Depreciation & amort. | −44 | −14 | −7 | — | −34 |
| EBIT | 56 | 985 | −661 | 267 | 627 |
| Net financials | −1 | 0 | 4 | −4 | 1 |
| Profit before tax | 55 | 985 | −657 | 263 | 628 |
| Tax | −11 | −178 | −0 | — | −127 |
| Net profit | 44 | 807 | −657 | 263 | 501 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 229 | 1 651 | 854 | 846 | 744 |
| Equity | 139 | 957 | 227 | 286 | 552 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 90 | 695 | 627 | 560 | 192 |
| Total debt | 90 | 695 | 627 | 560 | 192 |
EBITDA margin
34.7%
This company
15.8%
Market median
+120% vs market
20212025
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20212025
Return on equity
90.8%
This company
18.4%
Market median
+393% vs market
20212025
Net profit margin
26.3%
This company
8.1%
Market median
+225% vs market
20212025
Asset turnover
2.56×
This company
1.12×
Market median
+129% vs market
20212025
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AI Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TeimMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Adil Idris | Chief Executive Officer | 0 companies |
| Marie Eleonor Eriksson | Deputy Board Member | 0 companies |